Wednesday, August 26, 2026 1 PM-2 PM ET
Learn about digital pathology technology that is future-ready, yet practical for today’s
laboratory needs.
Webinar presenters Scott Hammond, Senior Systems Consultant, Digital Pathology Division, Wexner Medical Center, Department of Pathology, and Ursula Hofer, Imaging Technologist, Pathology Digital Imaging Lab, Wexner Medical Center, Department of Pathology, and Sandra Banky, PA(ASCP), Director of Operations, Wexner Medical Center, Department of Pathology, and Molly Epler, MHI, LSSYB, Clinical Laboratory Manager, Wexner Medical Center.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Wednesday, September 23, 2026. 12 PM-12:30 PM ET
Roundtable presenters Dr. David Sacks MB, ChB, FRCPath, Chairman, Steering Committee National Glycohemoglobin Standardization Program (NGSP), and Priya Sivaraman, PhD, Senior Technical Product Manager, Tosoh Bioscience.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Wednesday, September 30, 2026. 1 PM-1:30 PM ET
Roundtable presenters John Longshore, PhD, Head of Scientific Affairs, Global Oncology Diagnostics, AstraZeneca, and Flora Berisha, MS, Executive Director, Global Head of Diagnostic Partnering and Development, Johnson & Johnson Innovative Medicine, and Mark D. Ewalt, MD, Associate Medical Director for Laboratory Operations, Diagnostic Molecular Pathology, Molecular Diagnostics Service, Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, and Isabel Preeshagul, DO, MBS, Thoracic Medical Oncologist, Memorial Sloan Kettering Cancer Center.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
August 2026—Testing for homologous recombination deficiency (HRD) is not for the faint of heart. Even the experts agree. Tricia Numan, MD, says that when she first became involved in the topic, “I didn’t realize how many components went into HRD testing,” including germline alterations, somatic alterations, and various classifications of genomic instability.
August 2026—In a summer of more ticks, more diseases, and more tick species expanding to new areas and bringing diseases with them, what Bobbi Pritt, MD, MSc, would like to see are more—and better—diagnostics in early Lyme disease. Laboratory scientists are inching toward improved solutions, though nothing is commercially available now. “I’m cautiously optimistic. I wouldn’t say I’m excited yet,” says Dr. Pritt, co-director of vector-borne diseases laboratory services and chair of the Division of Clinical Microbiology at Mayo Clinic in Rochester.
August 2026—Recognizing and reporting histologic subtypes and divergent differentiation in urothelial carcinoma is critical for diagnosis, prognosis, and treatment. “Ideally, you want to mention the subtype histologies in pathology reports and quantify the amount,” said Francesca Khani, MD, associate professor in the Department of Pathology and Laboratory Medicine and in the Department of Urology, Weill Cornell Medicine. In a CAP25 session last fall, Dr. Khani spoke of the mimics of benign entities and of other malignancies.
August 2026—Would artificial intelligence as an aid in ordering laboratory tests and making reports understandable to patients be a worry or a welcome step? In a June 2 online roundtable led by CAP TODAY publisher Bob McGonnagle, a Compass Group member shared what he learned about an Epic pilot, and that launched the following conversation about the clinical laboratory and pathology reports that could be made easier for patients to understand. One participant’s view: “proceed with caution.”
August 2026—A series of hands-on or role-playing workshops created by pathology student interest group leaders at a California medical school introduced pathology to dozens of students who would have otherwise completed their curriculum without that exposure.
August 2026—The 2022 World Health Organization and International Consensus Classification frameworks recognize several well-defined myeloid neoplasm categories that arise in the setting of inherited genetic predisposition. These entities are grouped according to associated clinical features and include myeloid neoplasms with germline predisposition in the absence of antecedent platelet abnormalities or organ dysfunction (e.g. CEBPA, DDX41, and TP53), those associated with inherited platelet disorders (e.g. RUNX1, ANKRD26, and ETV6), and disorders linked to underlying or potential organ dysfunction.
August 2026—Although cytologists and cytopathologists expend considerable effort in screening, risk stratification, diagnosis, staging, and prognostication, clinicians are increasingly demanding ancillary testing that predicts response or resistance to the broad range of therapeutic agents available to them. In advanced-stage non-small cell lung carcinoma, these therapies include tyrosine kinase and other small-molecule inhibitors, bispecific antibodies, and antibody-drug conjugates.
August 2026—Pediatric pathology remains a relatively small subspecialty within anatomic pathology. The American Board of Pathology since 1990 has issued only 648 subspecialty certificates in pediatric pathology, and between 2020 and 2024, only 14 to 21 candidates sat for the pediatric pathology certifying examination each year.
August 2026—Cytology specimens have long played a central role in primary diagnosis, with fine-needle aspiration often serving as the first—and sometimes only—procedure performed before treatment decisions are made. However, when molecular testing is needed, cytology material is still often viewed through a histology-centered lens: Is there a cell block or core biopsy?
August 2026—At the upcoming CAP26 annual meeting in Las Vegas, you might notice key differences compared with our past meetings. We know some elements that were once compelling reasons to attend conferences, such as CME credits, are no longer the draw they used to be.
